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Background: Limited information exists on the impact of tumor necrosis factor inhibition on 
COPD exacerbations. This retrospective study characterized this impact among COPD patients 
with underlying autoimmune conditions, exposed to tumor necrosis factor inhibitors (TNFi) 
and/or non-biologic disease-modifying antirheumatic drugs (DMARDs).
Patients and methods: Adult COPD patients with 1 diagnosis for rheumatoid arthritis 
(RA), psoriasis (PsO), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) before or 
within 6 months following the index COPD diagnosis were identified from the Truven Health 
MarketScan® databases. Patients were required to have a second claim for RA, PsO, PsA, AS, 
or DMARD use (biologic or non-biologic) prior to or up to 6 months following the index date. 
Incidence of COPD-related hospitalizations and emergency room (ER) visits was evaluated in 
relation to treatment with TNFi and/or DMARDs and other potential risk factors.
Results: The study cohort included 40,687 patients (untreated, 37.7%; non-biologic DMARD, 
35.4%; TNFi + non-biologic DMARD, 18%; TNFi, 8.8%). The proportion of patients with 
a COPD-related hospitalization and the incidence of COPD-related hospitalization (per 100 
person-years) were lowest in the TNFi cohort (8.6%; 3.54, 95% confidence interval [CI]: 
3.16–3.95) and the TNFi + non-biologic DMARD cohort (8.4%; 2.85, 95% CI: 2.63–3.08). 
In multivariate models, treatment with TNFi + non-biologic DMARD reduced the risk of 
COPD-related hospitalization or ER visits by 32% relative to non-biologic DMARDs (hazard 
ratio: 0.68; 95% CI: 0.61–0.75).
Conclusion: In real-world settings, TNFi monotherapy confers similar risk for COPD-related 
hospitalization or ER visits as a non-biologic DMARD. Decreased risk was found among those 
treated with both TNFi and a non-biologic DMARD.
Keywords: COPD, TNF inhibitor, exacerbation, incidence, biologic DMARD
Introduction
COPD, characterized by airflow limitation, affects 13 million adults in the US.1 
Current treatments, including inhaled corticosteroids, bronchodilators, and anticho-
linergics primarily provide symptomatic relief and appear to have little impact on 
natural disease history.2,3 In healthy individuals, inhalation of tumor necrosis factor 
alpha (TNF-α) has been shown to increase airway hyper-responsiveness, one of the 
key symptoms in COPD.4,5 Further research has shown an excess of proinflammatory 
cytokines, specifically TNF-α, in the sputum of patients with COPD.6–9 Thus, it is 
theorized that this cytokine, TNF-α, may play a major role in maintaining the inflam-
matory state from which COPD patients suffer, and treatment with tumor necrosis 
factor inhibitors (TNFi) may help reduce airway inflammation.10
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Studies have sought to examine the efficacy of TNFi 
in patients with COPD, both directly and indirectly, with 
mixed results.10–13 A randomized clinical trial with etaner-
cept failed to demonstrate efficacy in COPD relative to oral 
prednisone; however, the study was limited by the short 
treatment duration (two doses) and timing of the treatment 
(ie, during an acute exacerbation).14 The most compelling 
evidence for efficacy of TNFi in COPD stems from a large 
observational study of 15,771 patients with rheumatoid 
arthritis (RA) and COPD being treated with etanercept 
or infliximab.13 Treatment with etanercept was associated 
with a significant reduction in the risk of COPD-related 
hospitalization (relative risk [RR]: 0.49, 95% confidence 
interval [CI]: 0.29–0.82), whereas infliximab did not exhibit 
any significant impact. Along with TNF-α, lymphotoxin 
alpha (LTα) is a cytokine produced by lymphocytes which 
mediates a variety of inflammatory processes. The exact 
role of LTα, which etanercept uniquely inhibits among the 
available TNF blocking agents in COPD is unknown, but 
its expression is upregulated in the sputum and lung tissue 
of COPD patients.15
Results of these studies suggest the potential for benefit of 
treatment with TNFi among patients with COPD, however, 
small sample sizes, short study periods, and analysis of few 
TNFi in these studies limit any conclusive findings. Thus, 
we sought to take advantage of TNFi use in the treatment 
of autoimmune disorders (RA, psoriasis [PsO], psoriatic 
arthritis [PsA], and ankylosing spondylitis [AS]) since 2006 
where the majority of evaluated products were approved 
during the study period. Using administrative claims data, 
this study identified patients with one of the above disorders 
along with a diagnosis of COPD in order to characterize the 
risk of COPD hospitalizations and emergency room (ER) 
visits among patients who were exposed to TNFi and/or 
non-biologic disease-modifying antirheumatic drugs 
(DMARDs).
Patients and methods
Data source
This retrospective study employed the 2006–2013 Truven 
Health Analytics MarketScan® Commercial Claims and 
Encounters (Commercial) and Medicare Supplemental 
(Medicare) databases, which profile the health care experi-
ence (inpatient and outpatient) of individuals with employer- 
sponsored primary or Medicare supplemental health insur-
ance. These databases contain only deidentified data and 
therefore Institutional Review Board approval to conduct 
this study was not necessary.
Patient selection
Adults 18 years old with a primary or secondary diagnosis 
for COPD (International Classification of Diseases, Ninth 
Revision, Clinical Modification [ICD-9-CM] 490.xx-492.
xx, 496.xx) on a non-diagnostic claim (a service that was 
not performed to test for or ‘rule out’ a diagnosis) between 
January 1, 2006 and June 30, 2012 were identified (date of 
first COPD diagnosis = index date). Additionally, patients 
were required to have an inpatient or outpatient claim with a 
non-diagnostic diagnosis for RA (ICD-9-CM: 714.0x), PsO 
(ICD-9-CM: 696.1x), PsA (ICD-9-CM: 696.0x), or AS (ICD-
9-CM: 720.0x), and a second claim for RA, PsO, PsA, or AS, 
or use of a biologic or non-biologic DMARDs prior to or up 
to 6 months following the index date. Treatment of Crohn’s 
disease (ICD-9-CM: 555.xx) or ulcerative colitis (ICD-9-CM: 
556.xx) can include very different dosing schedules that may 
impact study outcomes, thus, patients with a diagnosis of 
either in the pre- and post-period were excluded.
Patients were further stratified into four treatment cohorts 
based on the use of TNFi or non-biologic DMARDs dur-
ing the variable-length follow-up period: 1) TNFi only 
(adalimumab, certolizumab, etanercept, infliximab, goli-
mumab) cohort; 2) TNFi + non-biologic DMARD (metho-
trexate, minocycline, sulfasalazine, hydroxychloroquine, 
leflunomide, cyclosporine, azathioprine, and gold sodium 
thiomalate) cohort; 3) Non-biologic DMARD only cohort; 
and 4) Untreated cohort. Treatment cohorts were mutually 
exclusive, patient data was only included in one treatment 
cohort based upon evidence of TNFi and/or non-biologic 
DMARD use during the post-index period.
study outcomes
The proportion of patients having a COPD-related hospital-
ization was reported, and the incidence of COPD-related hos-
pitalization per 100 person-years was assessed for each of the 
four treatment cohorts. Patients were followed with a fixed 
length of 12-month pre-index period and a variable length 
post-index period with a minimum of 12 months. Person-
time at risk was defined as the time since index date to one 
of the following events, whichever occurred first: 1) COPD 
hospitalization, 2) inpatient death, 3) the end of enrollment, 
or 4) the end of data availability (June 30, 2013). In addition, 
a sensitivity analysis to test the robustness of the results was 
conducted to evaluate incidence of COPD-related ER visits 
or first COPD-related hospitalization. Patients with an ER 
visit prior to a COPD hospitalization were followed until 
the date of hospitalization for the primary study outcome. 
COPD-related hospitalizations were identified by primary 
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or secondary diagnosis of COPD on any inpatient claims 
during the post-period. If the index COPD diagnosis was on 
an inpatient claim, the start of the study outcome evaluation 
period was shifted to the day following the discharge date 
of the index hospitalization. COPD-related ER visits were 
captured by primary or secondary diagnosis of COPD for ER 
services resulting in patients being discharged home.
Other variables
Patient demographic characteristics and clinical charac-
teristics, including the Deyo-Charlson Comorbidity Index, 
comorbid medical conditions (1 medical claim) and 
concomitant medications (1 prescription claim) were 
measured at index date and during the 12-month pre-index 
period, respectively.
statistical methods
Proportional hazards regression analyses were performed 
to identify factors contributing to the risk of COPD-
related hospitalization or ER use. The explanatory items 
included patient treatment cohort (TNFi only, TNFi + non-
biologic therapies, non-biologic DMARD only [reference]), 
baseline demographic characteristics, comorbidities and 
medication exposure. Analyses were conducted using SAS 
9.3 (SAS Institute Inc., Cary, NC, USA).
Results
A total of 40,687 patients met study eligibility criteria and 
were included in the analysis. Of these, 15,347 (37.7%) were 
not treated with either a TNFi or DMARD, 14,420 (35.4%) 
were treated with a non-biologic DMARD only, 7,337 
(18.0%) were treated with both a TNFi and a non-biologic 
DMARD, and 3,583 (8.8%) received treatment with a TNFi 
only (Figure 1) during the post-index follow-up period.
Overall, patients had an average age of 59.8 years 
(standard deviation [SD] 13.9 years). The majority were 
females (67.3%), covered by a capitated health plan (90.9%), 
and resided in the South region of the US (36.6%) (Table 1); 
this distribution matches that of the underlying data source. 
There were some notable differences among the four treat-
ment cohorts. In particular, the TNFi only cohort was 
younger, and had the highest proportion of males (41.8%). 
Patients were followed for a mean of 830 days (SD 634 days), 
with the longest for the TNFi + non-biologic DMARD cohort 
Figure 1 Patient selection.
Abbreviations: as, ankylosing spondylitis; DMarD, disease-modifying antirheumatic drug; Psa, psoriatic arthritis; PsO, psoriasis; ra, rheumatoid arthritis; TnFi, tumor 
necrosis factor-alpha inhibitor.
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(1,073 days, SD 648 days) and the shortest for the untreated 
cohort (757 days, SD 580 days) (Table 1).
Patients in the TNFi only cohort had slightly lower 
Deyo-Charlson Comorbidity Index scores during the baseline 
period. The most prevalent comorbidities included hyperten-
sion (45.0%), hyperlipidemia (28.1%), and Type II diabetes 
(17.6%) with the highest prevalence seen in the untreated 
cohort. Over one-half of the patients had RA during the 
baseline with the highest proportion seen in TNFi + non-
biologic DMARD (78.3%) and non-biologic DMARD only 
(70.5%) cohorts. Nearly one-in-four patients were diagnosed 
with PsO, with the highest in the TNFi only (39.8%) or the 
untreated cohort (39.7%). During the 12-month pre-period, 
44.3%, 35.5%, and 23.8% of study patients were treated with 
oral, intravenous (IV), and inhaled corticosteroids, respec-
tively, and 19.2%, 10.0%, and 2.7% were on short-acting 
beta-agonist (SABA), long-acting beta-agonist (LABA), 
and long-acting anti-muscarinics, respectively. The use of 
these medications increased during the follow-up period. 
The TNFi + non-biologic DMARD and the DMARD only 
cohorts consistently had higher use of these concomitant 
medications than the TNFi only and the untreated cohorts; 
the same pattern was observed for pre-period antibiotics 
use (Table 2).
The proportion of patients who had a COPD-related 
hospitalization during the follow-up period was lower for 
the TNFi only (8.6%) and the TNFi + non-biologic DMARD 
cohort (8.4%) than that for the non-biologic DMARD only 
(11.7%, both P0.0001) and the untreated cohort (14.2%, 
both P0.0001). Figures 2 and 3 display the unadjusted 
and adjusted time to first COPD-related hospitalization. The 
untreated cohort had the shortest mean time from the index 
COPD diagnosis to the first COPD-related hospitalization 
(356 days, SD 451 days). Incidence rates of COPD-related 
hospitalization per 100 person-years were lowest in the 
TNFi + non-biologic DMARD (2.85; 95% CI: 2.63–3.08) 
and the TNFi only cohorts (3.54; 95% CI: 3.16–3.95). Similar 
patterns were observed in a sensitivity analysis expanding 
the study outcome to include either COPD-related ER visit 
or first COPD-related hospitalization.
Results from multivariable analysis revealed that use of 
TNFi treatment + non-biologic DMARD reduced the risk of 
COPD-related hospitalization or ER visits by 32%, relative to 
the non-biologic DMARD only patients (hazard ratio [HR]: 
0.678; 95% CI: 0.61–0.754). The hazard of hospitalization or 
ER visit between the TNFi only cohort and the non-biologic 
DMARD only cohort was statistically similar (HR: 1.003; 95% 
CI: 0.862–1.167). After adjusting for other covariates includ-
ing biologic and non-biologic DMARD use, hazard of COPD-
related hospitalization or ER visit were significantly higher in 
older patients (aged 45–54, 55–64, and 65 years) as com-
pared with patients aged 18–44 (P0.05 for all). Females had 
a lower hazard of hospitalization or ER visit than males (HR: 
0.828; 95% CI: 0.767–0.894) (Figure 4). Biologic DMARD 
use (adalimumab, infliximab, and etanercept), concomitant 
medication use (self-administered corticosteroids, SABA, 
Table 1 Patient demographic characteristics
Demographic  
characteristics
All patients TNFi only TNFi + DMARD DMARD only Untreated
N=40,687 n=3,583 n=7,337 n=14,420 n=15,347
age (years), mean (sD) 59.8 (13.9) 55.0 (13.5) 57.3 (12.0) 61.9 (13.1) 60.2 (15.0)
age group (years), n (%)
18–34 1,720 (4.2) 258 (7.2) 280 (3.8) 380 (2.6) 802 (5.2)
35–44 3,531 (8.7) 497 (13.9) 739 (10.1) 914 (6.3) 1,381 (9.0)
45–54 8,240 (20.3) 947 (26.4) 1,769 (24.1) 2,548 (17.7) 2,976 (19.4)
55–64 13,329 (32.8) 1,094 (30.5) 2,702 (36.8) 4,829 (33.5) 4,704 (30.7)
65 13,867 (34.1) 787 (22.0) 1,847 (25.2) 5,749 (39.9) 5,484 (35.7)
Female, n (%) 27,373 (67.3) 2,087 (58.3) 5,370 (73.2) 10,283 (71.3) 9,633 (62.8)
geographic region, n (%)
northeast 6,280 (15.4) 538 (15.0) 950 (13.0) 2,080 (14.4) 2,712 (17.7)
north Central 12,556 (30.9) 1,002 (28.0) 2,166 (29.5) 4,704 (32.6) 4,684 (30.5)
south 14,891 (36.6) 1,419 (39.6) 2,919 (39.8) 5,202 (36.1) 5,351 (34.9)
West 6,588 (16.2) 587 (16.4) 1,243 (16.9) 2,323 (16.1) 2,435 (15.9)
Unknown 372 (0.9) 37 (1.0) 59 (0.8) 111 (0.8) 165 (1.1)
Insurance plan type, n (%)
Capitated 36,967 (90.9) 3,259 (91.0) 6,649 (90.6) 13,084 (90.7) 13,975 (91.1)
non-capitated 3,720 (9.1) 324 (9.0) 688 (9.4) 1,336 (9.3) 1,372 (8.9)
Days of follow-up, mean (sD) 882 (614) 888 (591) 1,073 (648) 905 (609) 767 (580)
Abbreviations: DMarD, disease-modifying antirheumatic drug; sD, standard deviation; TnFi, tumor necrosis factor inhibitors.
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LABA, ipratropium bromide, long-acting anti-muscarinics, 
and theophylline), and several comorbidities (anxiety, con-
gestive heart failure, depression, hypertension, obesity, and 
osteoporosis) were all significantly associated with increased 
risk of COPD-related hospitalization or ER visit (All P0.05) 
(Figure 5). Sensitivity analysis conducted among only patients 
with a diagnosis of RA were similar to the overall results.
Analysis of an array of clinical and demographic factors 
among COPD patients who underwent different treatments 
showed that older patients, those with worse general health 
and select preexisting comorbid conditions, and pretreatment 
with COPD medications (SABAs, LABAs, long-acting anti-
muscarinics, theophylline, and TNFi) had increasing hazards 
for COPD-related hospitalization or ER visits. Stratified 
analysis was conducted where four additional Cox models 
were fit for patients in age groups 18–44, 45–54, 55–64, and 
65 years. The findings were consistent with those for the 
combined sample. The use of combination TNFi and non-
biologic DMARD therapy was associated with a reduction 
in the hazard of COPD-related hospitalization or ER visits 
compared to non-biologic DMARD only in all age groups, 
though not statistically significant for the youngest age group: 
18–44 years (HR: 0.877; 95% CI: 0.561–1.373), 45–54 
years (HR: 0.731; 95% CI: 0.563–0.949), 55–64 years (HR: 
0.619; 95% CI: 0.513–0.747), and 65 years (HR: 0.700; 
95% CI: 0.596–0.823). Similarly, there were no statistically 
significant differences between the TNFi only cohort and 
the non-biologic DMARD only cohort across all four age 
subgroups (Table S1). The combined model also found that 
the presence of pre-index period asthma, AS, and PsO were 
each associated with lower hazard of COPD-related hospi-
talization or ER visits during follow-up (Figure 5).
Table 2 Patient clinical characteristics
Clinical characteristics All patients TNFi only TNFi + DMARD DMARD only Untreated
N=40,687 n=3,583 n=7,337 n=14,420 n=15,347
Deyo-Charlson Comorbidity Index, mean (sD) 1.5 (1.6) 1.1 (1.4) 1.4 (1.2) 1.7 (1.5) 1.5 (1.8)
Baseline comorbid conditions, n (%)
anxiety 2,990 (7.3) 260 (7.3) 474 (6.5) 913 (6.3) 1,343 (8.8)
asthma 5,209 (12.8) 424 (11.8) 922 (12.6) 1,963 (13.6) 1,900 (12.4)
Congestive heart failure 2,714 (6.7) 137 (3.8) 260 (3.5) 1,011 (7.0) 1,306 (8.5)
Depression 4,220 (10.4) 342 (9.5) 755 (10.3) 1,422 (9.9) 1,701 (11.1)
hyperlipidemia 11,423 (28.1) 899 (25.1) 1,658 (22.6) 3,938 (27.3) 4,928 (32.1)
hypertension 18,314 (45.0) 1,397 (39.0) 2,873 (39.2) 6,678 (46.3) 7,366 (48.0)
Obesity 2,138 (5.3) 194 (5.4) 320 (4.4) 671 (4.7) 953 (6.2)
Osteoarthritis 5,992 (14.7) 441 (12.3) 1,101 (15.0) 2,240 (15.5) 2,210 (14.4)
Osteoporosis 3,060 (7.5) 179 (5.0) 576 (7.9) 1,316 (9.1) 989 (6.4)
Pneumonia 1,606 (3.9) 98 (2.7) 216 (2.9) 623 (4.3) 669 (4.4)
Type 2 diabetes 7,179 (17.6) 594 (16.6) 1,069 (14.6) 2,495 (17.3) 3,021 (19.7)
Pre-index TnFi indicated condition, n (%)
rheumatoid arthritis 23,101 (56.8) 1,514 (42.3) 5,747 (78.3) 10,165 (70.5) 5,675 (37.0)
Psoriasis 9,633 (23.7) 1,425 (39.8) 768 (10.5) 1,351 (9.4) 6,089 (39.7)
Psoriatic arthritis 3,002 (7.4) 675 (18.8) 817 (11.1) 753 (5.2) 757 (4.9)
ankylosing spondylitis 1,057 (2.6) 260 (7.3) 172 (2.3) 158 (1.1) 467 (3.0)
Pre-index concomitant medications, n (%)
Oral/self-administered corticosteroids 18,042 (44.3) 1,272 (35.5) 4,049 (55.2) 7,776 (53.9) 4,945 (32.2)
IV corticosteroids 14,455 (35.5) 1,147 (32.0) 3,064 (41.8) 5,387 (37.4) 4,857 (31.6)
Inhaled corticosteroids 9,693 (23.8) 814 (22.7) 1,940 (26.4) 3,784 (26.2) 3,155 (20.6)
saBa 7,797 (19.2) 664 (18.5) 1,513 (20.6) 3,059 (21.2) 2,561 (16.7)
laBa 4,079 (10.0) 342 (9.5) 825 (11.2) 1,622 (11.2) 1,290 (8.4)
long-acting anti-muscarinics 1,092 (2.7) 90 (2.5) 192 (2.6) 455 (3.2) 355 (2.3)
antibiotics 28,513 (70.1) 2,461 (68.7) 5,522 (75.3) 10,678 (74.1) 9,852 (64.2)
Theophylline 211 (0.5) 13 (0.4) 36 (0.5) 88 (0.6) 74 (0.5)
Ipratropium bromide 2,032 (5.0) 142 (4.0) 343 (4.7) 846 (5.9) 701 (4.6)
Other biologics 113 (0.3) 3 (0.1) 14 (0.2) 68 (0.5) 28 (0.2)
Physician specialty at index COPD diagnosis, n (%)
rheumatologist 15,152 (37.2) 1,356 (37.8) 3,960 (54.0) 6,589 (45.7) 3,247 (21.2)
Dermatologist 11,306 (27.8) 1,375 (38.4) 1,464 (20.0) 2,966 (20.6) 5,501 (35.8)
Pulmonologist 3,521 (8.7) 294 (8.2) 628 (8.6) 1,431 (9.9) 1,168 (7.6)
Abbreviations: DMarD, disease-modifying antirheumatic drug; IV, intravenous; laBa, long-acting beta-agonist; saBa, short-acting beta-agonist; sD, standard deviation; 
TnFi, tumor necrosis factor inhibitors.
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Figure 2 Unadjusted probability of first COPD-related hospitalization by days after starting treatment.
Abbreviations: TnFi, tumor necrosis factor inhibitors; IP, inpatient.
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Discussion
This large retrospective database analysis of 40,687 COPD 
patients from a nationally representative health care 
administrative database found that patients on treatment 
containing TNFi had lower incidence rates of COPD-related 
hospitalization than patients treated with non-biologic 
DMARDs only or untreated patients. Similar findings were 
observed when expanding the study outcome to include both 
COPD-related ER visit and hospitalization. After adjusting 
for patient baseline demographic and clinical differences, 
TNFi + non-biologic DMARD treatment was associated 
with a significant reduction in the hazard of COPD-related 
hospitalization or ER visits compared to non-biologic 
DMARD only; however, there was no significant differ-
ence in the hazard of COPD-related hospitalization or ER 
visits between patients treated with TNFi only and those 
treated with non-biologic DMARD only. TNFi are routinely 
combined with non-biologic DMARDs such as methotrex-
ate for additional efficacy though monotherapy is often 
employed due to adverse events such as gastrointestinal 
discomfort, hepatic laboratory abnormalities, and hemato-
logic cytopenias.16
In 2008, a large claims-based analysis of RA and COPD 
patients treated with etanercept and infliximab reported 
significant reduction in the risk of COPD-related hospital-
ization with the use of TNFi (RR: 0.62; 95% CI: 0.43–0.89) 
compared to the untreated, exclusively driven by etanercept 
(RR: 0.49; 95% CI: 0.29–0.82).13 However, infliximab did 
not have the same effect on risk reduction of hospitalization 
(RR: 0.95; 95% CI: 0.59–1.52). Our current analysis was 
built upon this approach, with the following differences: more 
recent claims data (2006–2013 versus 1995–2004), larger 
sample size (40,687 versus 15,771), younger patient sample 
(mean age of 60 years versus 67 years), and longer duration 
of follow-up (mean 28 months versus 14 months).13 Another 
key difference is that our analysis differentiated TNFi mono-
therapy from TNFi plus concomitant non-biologic DMARD 
therapy, whereas Suissa et al13 treated both together. Our 
study also examined TNFi as a class and did not evaluate the 
outcomes by individual agent. While differential outcomes 
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Figure 3 adjusteda probability of first COPD-related hospitalization by days after starting treatment.
Notes: aadjusted for age, gender, region, baseline CCI, baseline diagnosis of: ra, Psa, PsO, as, hypertension, pneumonia, asthma, Type 2 diabetes, obesity, depression, 
hyperlipidemia, osteoporosis, congestive heart failure, anxiety, and baseline use of: non-biologic DMarD, oral/self-administered corticosteroids, inhaled corticosteroids, 
physician-administered corticosteroids, laBa, saBa, long-acting anti-muscarinics, ipratropium bromide, antibiotics, and baseline biologic use (eTa, aDa, InF, gOl, CTZ, 
or other).
Abbreviations: as, ankylosing spondylitis; CCI, Deyo-Charlson Comorbidity Index; DMarD, disease-modifying antirheumatic drug; Psa, psoriatic arthritis; PsO, psoriasis; 
ra, rheumatoid arthritis; laBa, long-acting beta-agonist; saBa, short-acting beta-agonist; TnFi, tumor necrosis factor inhibitors; IP, inpatient; eTa, etanercept; aDa, 
adalimumab; INF, infliximab; GOL, golimumab; CTZ, certolizumab.
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Figure 4 hazard ratio of COPD-related hospitalization or er visits during 3-year follow-up period.
Note: Hazard ratios with 95% confidence intervals.
Abbreviations: er, emergency room; TnFi, tumor necrosis factor inhibitors.
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Figure 5 hazard ratio of COPD-related hospitalization or er visits during 3-year follow-up period, all ages combined.
Notes: referent for medication use is no pharmacy claims during pre-index period. referent for comorbidities is no diagnoses during pre-index period. referent for 
comorbidity score is 0 during pre-index period. Hazard ratios with 95% confidence intervals.
Abbreviations: DMarD, disease-modifying antirheumatic drug; er, emergency room; IV, intravenous.
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for infliximab and etanercept have been reported in the past, 
there are no known published studies on newer TNFi such as 
certolizumab pegol and golimumab.13 Future analysis at the 
drug level is desirable to test the findings from this study.
Limitations
The interpretation of findings from this study should be cau-
tioned with several limitations. Channeling bias may be present 
in this analysis and occurs when a high-risk subset of patients 
are less likely to be prescribed certain medications than other 
low-risk patients. Patients in all cohorts had comparable comor-
bidity scores and though comorbidities were controlled for in 
the adjusted models, the potential for channeling bias remains, 
especially if it is related to disease severity or other unobservable 
patient characteristics that could influence the study outcomes. 
Other limitations stem from using health insurance claims. 
The identification of diagnosis relied on ICD-9 diagnosis codes 
which only reflect the claims which physicians submit for 
reimbursement. Additionally, past studies have suggested that 
COPD severity, timing of treatment (ie, during an acute exac-
erbation) and subtype of COPD may influence the efficacy of 
TNFi in treating COPD.10–12,17 We were unable to capture these 
clinical markers using medical claims and thus our findings 
warrant further investigation within different subsets of COPD 
patients incorporating this clinical data. Finally, this study only 
included patients covered by commercial or Medicare insur-
ance, therefore results may not be generalizable to those with 
other types of coverage or the uninsured.
Conclusion
This retrospective study of COPD patients with underlying 
autoimmune conditions suggests that use of a TNFi alone 
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confers a similar risk for COPD-related hospitalizations 
compared to patients receiving a non-biologic DMARD 
alone; however, a decreased risk was apparent among those 
treated with both TNFi and a non-biologic DMARD. Multiple 
factors were found to be related to COPD hospitalization. 
Further analyses are needed to better understand the impact 
of disease severity (both COPD and autoimmune disease) 
and other factors in the physicians’ decision-making process 
as to which patients to treat with TNFi and whether there is a 
channeling of patients based on underlying disease profile.
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Table S1 adjusted relative risk of a COPD-related IP admission or er visit by age
Cohort All ages 18–44 years 45–54 years 55–64 years 65 years
HR P-value HR P-value HR P-value HR P-value HR P-value
TnFi only 1.003 0.97 0.530 0.09 0.999 0.99 1.175 0.24 1.002 0.99
TnFi and DMarD 0.678 0.0001 0.877 0.57 0.731 0.02 0.619 0.0001 0.700 0.0001
DMarD only 1.000 – 1.000 – 1.000 – 1.000 – 1.000 –
Note: ‘–’ indicates referent. 
Abbreviations: DMarD, disease-modifying antirheumatic drug; er, emergency room, hr, hazard ratio; IP, inpatient; TnFi, tumor necrosis factor-alpha inhibitor.
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